ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Premium IconPremium Help Menu
CAC 40
7 536,26
0,45%
Dow Jones
40 113,50
0,05%
DAX
22 242,45
0,78%
Brent Oil
66,025
0,00%
Bitcoin
93 895,54
-0,79%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) Actualités

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACRV
DateHeureSourceTitreSymboleSociété
25/04/202514h34Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ACRVAcrivon Therapeutics Inc
25/04/202514h32Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACRVAcrivon Therapeutics Inc
25/04/202514h30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACRVAcrivon Therapeutics Inc
25/04/202514h00GlobeNewswire Inc.Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025NASDAQ:ACRVAcrivon Therapeutics Inc
18/04/202521h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
07/04/202522h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
07/04/202522h05GlobeNewswire Inc.Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical OfficerNASDAQ:ACRVAcrivon Therapeutics Inc
03/04/202522h28Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
28/03/202514h08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRVAcrivon Therapeutics Inc
27/03/202522h44GlobeNewswire Inc.Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:ACRVAcrivon Therapeutics Inc
27/03/202521h06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRVAcrivon Therapeutics Inc
19/03/202513h00GlobeNewswire Inc.Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program UpdatesNASDAQ:ACRVAcrivon Therapeutics Inc
05/02/202514h00GlobeNewswire Inc.Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial CancerNASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202413h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
13/11/202413h00GlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
17/10/202414h00GlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
16/10/202422h00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
11/10/202414h00GlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
14/09/202409h10GlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
10/09/202414h00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
09/09/202413h00GlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
13/08/202414h00GlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
29/05/202414h00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
14/05/202414h00GlobeNewswire Inc.Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
24/04/202422h01GlobeNewswire Inc.Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D EventNASDAQ:ACRVAcrivon Therapeutics Inc
17/04/202402h01GlobeNewswire Inc.Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
10/04/202414h00GlobeNewswire Inc.Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable ResistancNASDAQ:ACRVAcrivon Therapeutics Inc
09/04/202413h00GlobeNewswire Inc.Acrivon Therapeutics Announces $130 Million Private Placement FinancingNASDAQ:ACRVAcrivon Therapeutics Inc
28/03/202413h00GlobeNewswire Inc.Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
05/03/202422h30GlobeNewswire Inc.Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACRV

Dernières Valeurs Consultées

BIT
WBELL
Bellini Nauttica
AMEX
FFLS
Future Fund Long short ETF
NASDAQ
VELO
Velocity Acquisition
BIT
P1R6W3
BNP Paribas Issuance
ASX
AL8OA
Alderan Resources
COIN
NECETH
DeversiFi Nectar Token
USOTC
ACNI
American Community Newsp... (CE)
USOTC
ARTM
American Nortel Communic... (PK)
USOTC
MYTEF
Telekom Malaysian (PK)
KUCN
AZEROUSDT
Aleph Zero
NASDAQ
DPMI
Dupont Photomasks
TSX
AFN.DB.G
Ag Growth
DOWI
DWCGAM
DJ US Gambling Total Sto...
COIN
JDIIUST
JDIToken
USOTC
MTVX
APT Moto Vox (CE)
COIN
KDIAUST
Global Diamond Platform Coin
Delayed Upgrade Clock
ADVFN Logo
France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces